Geoffrey T Gibney MD

Oncology•Washington, DC

Physician

Join to View Full Profile

3970 Reservoir Rd NWWashington, DC 20007
Phone+1 202-444-7064
Fax+1 202-444-1229

Education & Training

Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
Boston University Medical CenterResidency, Internal Medicine, 2005 - 2008
Uconn School Of MedicineClass of 2005

Certifications & Licensure

DC State Medical License 2015 - 2027
MD State Medical License 2019 - 2026
FL State Medical License 2011 - 2018
CT State Medical License 2008 - 2016
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma Start of enrollment: 2010 Aug 13
Completed
Phase 1
Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma Start of enrollment: 2012 Jul 27
Completed
Phase 1
Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma Start of enrollment: 2012 Aug 03
ACTIVE_NOT_RECRUITING
PHASE2
Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts Start of enrollment: 2012 Oct 09
ACTIVE_NOT_RECRUITING
NA
Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor Start of enrollment: 2012 Dec 01
Completed
Phase 1
A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma Start of enrollment: 2013 Jun 01
Completed
Phase 1, Phase 2
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064) Start of enrollment: 2013 Apr 30
Completed
Phase 2
Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma Start of enrollment: 2013 Oct 23
Completed
Phase 2
RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER Start of enrollment: 2013 Dec 31
COMPLETED
PHASE1
Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma Start of enrollment: 2014 Jan 07
Completed
Phase 1
Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Start of enrollment: 2014 May 29
TERMINATED
PHASE1
Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma Start of enrollment: 2014 Aug 12
Completed
Phase 2
Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma Start of enrollment: 2020 Mar 02
ACTIVE_NOT_RECRUITING
PHASE2
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial Start of enrollment: 2021 Feb 09
RECRUITING
PHASE2
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) Start of enrollment: 2019 Jul 18
RECRUITING
PHASE2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Large-Scale Multiomic Analysis Identifies Anatomic Differences and Immunogenic Potential in Subtypes of Leiomyosarcoma.
Galina Lagos, Roman Groisberg, Andrew Elliott, Don S Dizon, Andreas Seeber
Clinical Cancer Research. 2025-06-03
Cellular Therapy for Advanced Melanoma.
Jacob Zaemes, Geoffrey T Gibney
The Surgical Clinics of North America. 2025-06-01
Comprehensive Profiling of Acral Lentiginous Melanoma Reveals Downregulated Immune Activation Compared to Cutaneous Melanoma.
Stephanie J Wang, Joanne Xiu, Katherine M Butcher, Brittney K DeClerck, Gene H Kim
Pigment Cell & Melanoma Research. 2025-05-01

Press Mentions

Breakthrough, Life-Saving Cancer Treatment, TIL Therapy, Offers New Hope to Patients with Metastatic MelanomaJanuary 8th, 2025
Key Studies Conducted at Georgetown Lombardi Lead to Better Treatment for People with MelanomaMarch 1st, 2023
Advancement in Melanoma Treatment Found to Significantly Improve Survival Rates in PatientsSeptember 30th, 2022
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Geoffrey T Gibney MD

Dr. Gibney is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.